.jpg)
Berlin / Hamburg, November 4, 2025 – YPOG has provided comprehensive legal advice to lead investor Venrock Healthcare Capital Partners also on the second closing of the Series C financing round of biotech company Tubulis. With the completion of the second closing, the total volume of the financing round has been increased to 344 million EUR (401 million USD) – making it one of the largest private financings in European biotech history.
In addition to Venrock Healthcare Capital Partners, the investor circle expanded to include renowned new investors, including Fidelity Management & Research Company, Janus Henderson Investors, and Blackstone Multi-Asset Investing. Wellington Management, Ascenta Capital, and existing investors such as Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, HTGF, OCCIDENT, and Seventure Partners also participated in the first closing.
The additional funds will be used to accelerate the clinical development of the lead candidate TUB-040. In particular, the financing will enable the preparation of pivotal studies—i.e., Phase III clinical trials relevant for regulatory approval—which will pave the way for possible market approval. TUB-040 targets the tumor antigen NaPi2b, which is often particularly prominent in ovarian cancer and other solid tumors. At this year's ESMO (European Society for Medical Oncology) Congress in Berlin, Tubulis presented the first positive clinical data from its ongoing Phase I/IIa study.
In addition, the capital will be invested in the expansion of the ADC (antibody-drug conjugate) technology platforms. These proprietary systems combine targeted antibodies with highly effective cell-killing substances to precisely attack tumor cells while sparing healthy cells. With the additional funds, Tubulis plans to develop new drug components, develop combination therapies, and expand its pipeline with additional clinical and preclinical programs.
YPOG provided legal advice in close cooperation with the US law firm Cooley LLP under the leadership of James Schneider (partner, Boston).
“The second closing of Tubulis' Series C financing underscores how dynamically the European biotech ecosystem is developing,” says Dr. Benjamin Ullrich, co-Managing Partner at YPOG. “The entry of additional renowned international investors impressively confirms the confidence in Tubulis' scientific and technological excellence. The development of innovative ADC technologies shows that biometric research from Germany can set global standards.”
About Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners (VHCP) is a healthcare-focused, late-stage venture capital fund family that invests primarily in publicly-held and late-stage private companies within the healthcare and life sciences industries, with a strong emphasis on small-cap public companies and biotechnology. VHCP focuses on companies developing and commercializing innovative products and technologies. For more information, please visit venrock.com.
Team
Dr. Benjamin Ullrich (Lead, Transactions), Partner, Berlin
Stefan Richter (Tax), Partner, Hamburg
Dr. Benedikt Flöter (IP/IT/Data Protection), Partner, Berlin
Dr. Carolin Raspé (Corporate Crime + Compliance + Investigations), Partner, Munich
Dr. Emma Peters (Transactions), Associated Partner, Berlin
Tobias Lovett (Transactions), Associated Partner, Berlin
Pia Meven (Transactions), Associated Partner, Berlin
Anna Eickmeier (IP/IT/Data Protection), Senior Associate, Berlin
Theresia M.R. Heinrich (Transactions), Senior Associate, Berlin
Konstantina Nathanail (IP/IT/Data Protection), Associate, Berlin
Silke Ricken (Corporate), Associate, Berlin
Dr. Christian Busmann (Tax), Associate, Hamburg
Kontakt
About us
YPOG stands for You + Partners of Gamechangers – forward-thinking legal and tax advice. Supporting companies that are focused on emerging technologies, YPOG embraces change as an opportunity to develop cutting-edge solutions. The YPOG team offers comprehensive expertise in the areas of Funds, Tax, Transactions, Corporate, Banking, Regulatory + Finance, IP/IT/Data Protection, Litigation, and Corporate Crime + Compliance + Investigations. YPOG is one of the leading law firms in Germany for venture capital, private equity, fund structuring, and the implementation of distributed ledger technology (DLT) in financial services. Both the firm and its partners are regularly recognized by renowned national and international publications such as JUVE, Best Lawyers, Chambers and Partners, Leaders League, and Legal 500. YPOG is home to more than 180 experienced attorneys, tax advisors and tax specialists as well as a notary, working across offices in Berlin, Cologne, Hamburg, Munich, Cambridge and London.
Further information: www.ypog.law/en/ and www.linkedin.com/company/ypog